Drug Type Small molecule drug |
Synonyms HBW 3210, HBW-3-10, HBW-3210 + [1] |
Target |
Action inhibitors |
Mechanism BTK C481S inhibitors(Bruton Tyrosine Kinase C481S inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Primary cutaneous diffuse large cell B-cell lymphoma | Phase 2 | China | 09 Oct 2023 | |
| Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Phase 2 | China | 09 Oct 2023 | |
| Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma | Phase 2 | China | 09 Oct 2023 | |
| Waldenstrom Macroglobulinemia | Phase 2 | China | 09 Oct 2023 | |
| Refractory Mature B-Cell Non-Hodgkin Lymphoma | Phase 2 | China | 01 Sep 2023 | |
| Autoimmune Diseases | Phase 1 | China | - |





